These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 17641778

  • 21. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T.
    Cancer; 2005 May 01; 103(9):1800-9. PubMed ID: 15786421
    [Abstract] [Full Text] [Related]

  • 22. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, Moriuchi T.
    Int J Oncol; 2010 Oct 01; 37(4):869-77. PubMed ID: 20811709
    [Abstract] [Full Text] [Related]

  • 23. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
    Abouantoun TJ, MacDonald TJ.
    Mol Cancer Ther; 2009 May 01; 8(5):1137-47. PubMed ID: 19417143
    [Abstract] [Full Text] [Related]

  • 24. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA.
    Mol Cancer Ther; 2011 Nov 01; 10(11):2157-67. PubMed ID: 21885862
    [Abstract] [Full Text] [Related]

  • 25. PDGF BB induces VEGF secretion in ovarian cancer.
    Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH, Sledge GW.
    Cancer Biol Ther; 2007 Dec 01; 6(12):1951-9. PubMed ID: 18075302
    [Abstract] [Full Text] [Related]

  • 26. PDGF receptors as targets in tumor treatment.
    Ostman A, Heldin CH.
    Adv Cancer Res; 2007 Dec 01; 97():247-74. PubMed ID: 17419949
    [Abstract] [Full Text] [Related]

  • 27. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M.
    J Invest Dermatol; 2004 Feb 01; 122(2):400-5. PubMed ID: 15009722
    [Abstract] [Full Text] [Related]

  • 28. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.
    Falcon BL, Pietras K, Chou J, Chen D, Sennino B, Hanahan D, McDonald DM.
    Am J Pathol; 2011 Jun 01; 178(6):2920-30. PubMed ID: 21641409
    [Abstract] [Full Text] [Related]

  • 29. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer.
    Lindmark G, Sundberg C, Glimelius B, Påhlman L, Rubin K, Gerdin B.
    Lab Invest; 1993 Dec 01; 69(6):682-9. PubMed ID: 8264231
    [Abstract] [Full Text] [Related]

  • 30. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
    Yamaguchi SI, Ueki A, Sugihara E, Onishi N, Yaguchi T, Kawakami Y, Horiuchi K, Morioka H, Matsumoto M, Nakamura M, Muto A, Toyama Y, Saya H, Shimizu T.
    Cancer Sci; 2015 Jul 01; 106(7):875-82. PubMed ID: 25940371
    [Abstract] [Full Text] [Related]

  • 31. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 32. PDGF-BB is a novel prognostic factor in colorectal cancer.
    Nakamura Y, Tanaka F, Yoshikawa Y, Mimori K, Inoue H, Yanaga K, Mori M.
    Ann Surg Oncol; 2008 Aug 01; 15(8):2129-36. PubMed ID: 18478301
    [Abstract] [Full Text] [Related]

  • 33. Effect of platelet-derived growth factor-B on renal cell carcinoma growth and progression.
    Wang W, Qi L, Tan M, Zhang Z, Du J, Wei X, Yao X.
    Urol Oncol; 2015 Apr 01; 33(4):168.e17-27. PubMed ID: 25766258
    [Abstract] [Full Text] [Related]

  • 34. Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate.
    Chung R, Foster BK, Zannettino AC, Xian CJ.
    Bone; 2009 May 01; 44(5):878-85. PubMed ID: 19442606
    [Abstract] [Full Text] [Related]

  • 35. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate.
    Furuhashi M, Sjöblom T, Abramsson A, Ellingsen J, Micke P, Li H, Bergsten-Folestad E, Eriksson U, Heuchel R, Betsholtz C, Heldin CH, Ostman A.
    Cancer Res; 2004 Apr 15; 64(8):2725-33. PubMed ID: 15087386
    [Abstract] [Full Text] [Related]

  • 36. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy.
    van Steensel L, Paridaens D, Dingjan GM, van Daele PL, van Hagen PM, Kuijpers RW, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA.
    Invest Ophthalmol Vis Sci; 2010 Feb 15; 51(2):1002-7. PubMed ID: 19797221
    [Abstract] [Full Text] [Related]

  • 37. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
    Moawad EY.
    J Gastrointest Cancer; 2015 Sep 15; 46(3):272-83. PubMed ID: 25985771
    [Abstract] [Full Text] [Related]

  • 38. The effects of tumor-derived platelet-derived growth factor on vascular morphology and function in vivo revealed by susceptibility MRI.
    Robinson SP, Ludwig C, Paulsson J, Ostman A.
    Int J Cancer; 2008 Apr 01; 122(7):1548-56. PubMed ID: 18033683
    [Abstract] [Full Text] [Related]

  • 39. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.
    Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK, Cheng SY.
    Am J Pathol; 2003 Apr 01; 162(4):1083-93. PubMed ID: 12651601
    [Abstract] [Full Text] [Related]

  • 40. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D, Atherton JA, Ralston S, Szewc R, Kath JC, Lin J, Soderstrom C, Tkalcevic G, Cohen BD, Pollack V, Barth W, Hungerford W, Ung E.
    Cancer Res; 2005 Feb 01; 65(3):957-66. PubMed ID: 15705896
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.